Treatment of Lupus Erythematosus with Vitamin B12

Goldblatt, Samuel

doi:10.1038/jid.1951.98

Cited by 9 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…97 Others have also reported benefit with dapsone. 98 Other Topical imiquimod (Level of evidence = E) 99,100 Topical 5-fluorouracil (Level of evidence = C) 101 Topical tazarotene (Level of evidence = E) 102 Laser (Level of evidence = C) [103][104][105][106][107][108] Sulfasalazine (Level of evidence = D) [109][110][111][112] Interferon alfa (Level of evidence = C) [113][114][115][116] Methotrexate (Level of evidence = D) [117][118][119][120] Azathioprine (Level of evidence = E) [121][122][123] Phenytoin (Level of evidence = B) 124 Oral b-carotene (Level of evidence = E) 125 Cryotherapy (Level of evidence = E) [126][127][128][129] Suction blister grafts (Level of evidence = E) 130 Cyclophosphamide (Level of evidence = D) 131 Ultraviolet A1 (Level of evidence = E) 131 Extracorporeal photopheresis (Level of evidence = E) 132,133 Chimeric CD4 monoclonal antibodies (Level of evidence = E) 134 Colchicine (Level of evidence = E) 135 B 12 injections (Level of evidence = C) 136,137 Isoniazid (Level of evidence = E) 138 Mycophenolate mofetil (Level of evidence = E) 139,...…”

Section: Second-line Treatment Antimalarials (Level Of Evidence = A) mentioning

confidence: 99%

Management of primary cicatricial alopecias: options for treatment

et al. 2008

View full text Add to dashboard Cite

Primary cicatricial alopecias (PCAs) are a poorly understood group of disorders that result in permanent hair loss. Clinically, they are characterized not only by permanent loss of hair shafts but also of visible follicular ostia along with other visible changes in skin surface morphology, while their histopathological hallmark usually (although not always) is the replacement of follicular structures with scar-like fibrous tissue. As hair follicle neogenesis in adult human scalp skin is not yet a readily available treatment option for patients with cicatricial alopecias, the aim of treatment, currently, remains to reduce symptoms and to slow or stop PCA progression, namely the scarring process. Early treatment is the key to minimizing the extent of permanent alopecia. However, inconsistent terminology, poorly defined clinical end-points and a lack of good quality clinical trials have long made management of these conditions very challenging. As one important step towards improving the management of this under-investigated and under-serviced group of dermatoses, the current review presents evidence-based guidance for treatment, with identification of the strength of evidence, and a brief overview of clinical features of each condition. Wherever only insufficient evidence-based advice on PCA management can be given at present, this is indicated so as to highlight important gaps in our clinical knowledge that call for concerted efforts to close these in the near future.

show abstract